From July 1, 2023 to September 30, 2023, the company has repurchased 149,041 shares, representing 0.48% for $0.17 million. With this, the company has completed the repurchase of 4,708,520 shares, representing 14.3% for $15.42 million under the buyback announced on March 15, 2022.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.445 USD | -0.34% |
|
-9.12% | +8.65% |
06-14 | Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform | CI |
05-13 | HC Wainwright Adjusts Price Target on Co-Diagnostics to $2 From $2.50, Maintains Neutral Rating | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.65% | 45.35M | |
-34.21% | 14.7B | |
-52.14% | 2.33B | |
+23.01% | 1.96B | |
-10.06% | 1.52B | |
+21.24% | 1.24B | |
-23.46% | 904M | |
+1.33% | 784M | |
-34.13% | 750M | |
+23.58% | 597M |
- Stock Market
- Equities
- CODX Stock
- News Co-Diagnostics, Inc.
- Tranche Update on Co-Diagnostics, Inc.'s Equity Buyback Plan announced on March 15, 2022.